SARS-CoV-2 感染率与人群免疫:2020年3月至2021年5月新英格兰南部
该观察性病例系列评估2020年3月1日至2021年5月31日罗德岛、马萨诸塞和康涅狄格的新冠病例、住院、ICU占用、呼吸机占用和死亡,用贝叶斯推断框架估计2021年5月31日人群免疫构成。三州累计确诊1 160 435例,确诊者中位年龄38岁;2020年秋季三州人群免疫(即当时感染率)不足15%,为2020至2021年冬季大流行波埋下伏笔。2021年5月31日人群免疫估计为罗德岛73.4%(95%可信区间72.9%-74.1%)、康涅狄格64.1%(95%可信区间64.0%-64.4%)、马萨诸塞66.3%(95%可信区间65.9%-66.9%),提示2021年7月Delta变异株开始传播时三州超过33%居民完全易感。尽管疫苗覆盖率较高,罗德岛34.1%(95%可信区间32.9%-35.2%)、康涅狄格24.6%(95%可信区间24.3%-25.1%)、马萨诸塞27.6%(95%可信区间26.8%-28.6%)的疫苗被接种给已血清阳性者,使2021年夏季人群免疫低于计划。
要点
- 2020年秋季三州SARS-CoV-2人群免疫(即当时感染率)不足15%,随后出现2020至2021年冬季大流行波。
- 2021年5月31日人群免疫:罗德岛73.4%(95%可信区间72.9%-74.1%)、康涅狄格64.1%(95%可信区间64.0%-64.4%)、马萨诸塞66.3%(95%可信区间65.9%-66.9%)。
- 2021年7月Delta变异株开始传播时,三州超过33%居民对感染完全易感。
- 已血清阳性者接种疫苗比例:罗德岛34.1%(95%可信区间32.9%-35.2%)、康涅狄格24.6%(95%可信区间24.3%-25.1%)、马萨诸塞27.6%(95%可信区间26.8%-28.6%)。
- 三州累计确诊COVID-19 1 160 435例,确诊者中位年龄38岁。
适用人群与场景
- 罗德岛、马萨诸塞和康涅狄格三州居民,评估时间为2020年3月1日至2021年5月31日。
- 暴露定义为COVID-19检测阳性结果报告至州卫生部门。
研究设计与关键结果
- 研究类型为观察性病例系列,评估2020年3月1日至2021年5月31日罗德岛、马萨诸塞和康涅狄格三州的病例、住院、ICU占用、呼吸机占用和死亡,数据分析时间为2021年7月至2021年11月。
- 三州累计确诊COVID-19 1 160 435例,确诊者中位年龄38岁。
- 2020年秋季三州SARS-CoV-2人群免疫(等于当时感染率)不足15%。
- 2021年5月31日人群免疫估计:罗德岛73.4%(95%可信区间72.9%-74.1%)、康涅狄格64.1%(95%可信区间64.0%-64.4%)、马萨诸塞66.3%(95%可信区间65.9%-66.9%)。
- 2021年7月Delta变异株开始传播时,三州超过33%居民对感染完全易感。
- 已血清阳性者接种疫苗比例:罗德岛34.1%(95%可信区间32.9%-35.2%)、康涅狄格24.6%(95%可信区间24.3%-25.1%)、马萨诸塞27.6%(95%可信区间26.8%-28.6%)。
证据类型、等级与局限
- 证据类型:观察性病例系列。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来紧急情况下的疫苗接种规划可能不得不优先保证高疫苗覆盖率,而非优化疫苗分配,以确保在持续流行的疫情或大流行过程中达到足够的人群免疫水平。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In emergency epidemic and pandemic settings, public health agencies need to be able to measure the population-level attack rate, defined as the total percentage of the population infected thus far. During vaccination campaigns in such settings, public health agencies need to be able to assess how much the vaccination campaign is contributing to population immunity; specifically, the proportion of vaccines being administered to individuals who are already seropositive must be estimated.
OBJECTIVE: To estimate population-level immunity to SARS-CoV-2 through May 31, 2021, in Rhode Island, Massachusetts, and Connecticut.
DESIGN, SETTING, AND PARTICIPANTS: This observational case series assessed cases, hospitalizations, intensive care unit occupancy, ventilator occupancy, and deaths from March 1, 2020, to May 31, 2021, in Rhode Island, Massachusetts, and Connecticut. Data were analyzed from July 2021 to November 2021.
EXPOSURES: COVID-19-positive test result reported to state department of health.
MAIN OUTCOMES AND MEASURES: The main outcomes were statistical estimates, from a bayesian inference framework, of the percentage of individuals as of May 31, 2021, who were (1) previously infected and vaccinated, (2) previously uninfected and vaccinated, and (3) previously infected but not vaccinated.
RESULTS: At the state level, there were a total of 1 160 435 confirmed COVID-19 cases in Rhode Island, Massachusetts, and Connecticut. The median age among individuals with confirmed COVID-19 was 38 years. In autumn 2020, SARS-CoV-2 population immunity (equal to the attack rate at that point) in these states was less than 15%, setting the stage for a large epidemic wave during winter 2020 to 2021. Population immunity estimates for May 31, 2021, were 73.4% (95% credible interval [CrI], 72.9%-74.1%) for Rhode Island, 64.1% (95% CrI, 64.0%-64.4%) for Connecticut, and 66.3% (95% CrI, 65.9%-66.9%) for Massachusetts, indicating that more than 33% of residents in these states were fully susceptible to infection when the Delta variant began spreading in July 2021. Despite high vaccine coverage in these states, population immunity in summer 2021 was lower than planned owing to an estimated 34.1% (95% CrI, 32.9%-35.2%) of vaccines in Rhode Island, 24.6% (95% CrI, 24.3%-25.1%) of vaccines in Connecticut, and 27.6% (95% CrI, 26.8%-28.6%) of vaccines in Massachusetts being distributed to individuals who were already seropositive.
CONCLUSIONS AND RELEVANCE: These findings suggest that future emergency-setting vaccination planning may have to prioritize high vaccine coverage over optimized vaccine distribution to ensure that sufficient levels of population immunity are reached during the course of an ongoing epidemic or pandemic.
参考来源
- Tran TN, Wikle NB, Yang F, et al. SARS-CoV-2 Attack Rate and Population Immunity in Southern New England, March 2020 to May 2021. JAMA Netw Open. 2022. PMID: 35616938. doi:10.1001/jamanetworkopen.2022.14171
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。